StreetInsider.com News Articles

Defence Therapeutics to attend BIO International Convention 2026

Wed, 17 Jun 2026 03:17:08 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) plans to participate in the BIO International Convention 2026, scheduled for June 22-25 in San Diego, California, according to a company statement.

The Montreal-based biotechnology company said its team will be available at the conference to meet with pharmaceutical and biotechnology companies, investors, and potential collaborators to discuss partnership opportunities centered on its Accum® drug delivery platform.

Accum® is designed to enhance intracellular delivery through endosomal escape and improved targeting of cellular compartments. The platform is being applied to antibody-drug conjugates (ADCs) and radiopharmaceutical drug conjugates (RDCs).

Defence Therapeutics said it is seeking partnerships

Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions

Wed, 17 Jun 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - June 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce its participation in the BIO International Convention 2026, taking place June 22-25 in San Diego, California.

Defence's team will be available throughout the conference to meet with pharmaceutical and biotechnology companies, investors, and potential strategic collaborators interested in exploring partnership opportunities involving Defence's proprietary Accum^® platform.

Accum^® is designed to enhance intracellular delivery by promoting endosomal escape and improving delivery to target cellular compartments. The platform is being

Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions

Wed, 17 Jun 2026 03:15:00 -0400

Accum^® is designed to enhance intracellular delivery by promoting endosomal escape and improving delivery to target cellular compartments. The platform is being

Defence Therapeutics adds former Biogen executive to board

Wed, 03 Jun 2026 03:17:17 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) appointed Dr. John Beaver to its board of directors, the Montreal-based biotechnology company announced.

Dr. Beaver brings over 20 years of experience in pharmaceutical and biotechnology leadership roles. He most recently served as Vice President and Head of Global Biomarker Discovery & Development at Biogen, where he led biomarker and translational development activities for approximately 48 pipeline programs.

During his tenure at Biogen, Dr. Beaver contributed to biomarker-driven development strategies associated with FDA accelerated approvals in Alzheimer's disease and ALS. He previously held senior positions at AbbVie, where he served as Head of

Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors

Wed, 03 Jun 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Beaver to its Board of Directors. Dr. Beaver brings more than two decades of leadership experience across global pharmaceutical and biotechnology organizations.

Dr. Beaver has held senior leadership positions at several leading biopharmaceutical companies, including Biogen, AbbVie, and GlaxoSmithKline, where he contributed to the advancement of innovative therapeutic programs across multiple disease areas. His extensive experience spans translational medicine, biomarker discovery and development,

Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors

Wed, 03 Jun 2026 03:15:00 -0400

Defence Therapeutics adds ADC expert Dr. John Lambert to board

Mon, 01 Jun 2026 03:17:17 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) announced the appointment of Dr. John Lambert to its board of directors, effective immediately. The Montreal-based biotechnology company granted Lambert 150,000 stock options exercisable at 58 cents per share for five years.

Lambert brings over 40 years of experience in antibody-drug conjugate development. He previously held senior roles at ImmunoGen, including chief scientific officer and executive vice president of research. During his tenure, ImmunoGen scientists developed technologies that contributed to Genentech/Roche's KADCYLA therapy, approved in 2013 for HER2-positive breast cancer, and discovered the anti-CD38 antibody that became Sanofi's SARCLISA. AbbVie acquired ImmunoGen

Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors

Mon, 01 Jun 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - June 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Lambert to its Board of Directors, effective immediately. Dr. Lambert brings more than four decades of scientific leadership and pioneering expertise in the development of antibody-drug conjugates ("ADCs"), further strengthening Defence's strategic capabilities as the Company advances its ACCUM^®-enabled ADC platform and partnership programs.

Dr. Lambert is internationally recognized as one of the leading experts in the ADC field. He previously served in

Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors

Mon, 01 Jun 2026 03:15:00 -0400

Dr. Lambert is internationally recognized as one of the leading experts in the ADC field. He previously served in

Defence Therapeutics appoints Dr. Sarkis Meterissian to advisory board

Fri, 29 May 2026 16:32:12 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) announced that Dr. Sarkis Meterissian resigned from the company's board of directors to join its Scientific Advisory Board.

Dr. Meterissian serves as Director of the Breast Center at McGill University Health Centre and Head of the MUHC Breast Tumor Site Group. He had been on Defence's board of directors for five years before the transition.

The Scientific Advisory Board currently includes Rob Leanna, PhD, Danny Chui, PhD and Brendan Hussey, PhD. The Montreal-based biotechnology company develops precision intracellular drug-delivery technologies.

"Sarkis has been a strong believer in Defence's ACCUM platform since day one, and

Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian

Fri, 29 May 2026 16:30:00 -0400

Montreal, Quebec--(Newsfile Corp. - May 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, announces that Dr. Sarkis Meterissian resigned today from the Board of Directors of Defence to deepen engagement with the Company by joining the Scientific Advisory Board ("SAB").

Defence Therapeutics' current SAB is composed of Rob Leanna, PhD, Danny Chui, PhD and Brendan Hussey, PhD. The addition of Dr. Sarkis Meterissian, who is the Director of the Breast Center of the McGill University Health Centre ("MUHC") and the Head of the MUHC Breast

Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian

Fri, 29 May 2026 16:30:00 -0400

Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities

Tue, 19 May 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the expansion of internal capabilities to execute critical stages of its ACCUM^®-enabled Antibody Drug Conjugates ("ADC") development pipeline. The Company has strengthened its purification, analytical characterization, conjugation development, and quality control ("QC") capabilities, while enhancing cellular testing and potency evaluation workflows within a more structured stage-gated framework to better support the advancement of its ADC partnership programs.

"By strengthening our internal QC, analytical, and conjugation capabilities, Defence

Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities

Tue, 19 May 2026 03:15:00 -0400

"By strengthening our internal QC, analytical, and conjugation capabilities, Defence

Defence Therapeutics Announces Grant of Restricted Stock Units

Fri, 24 Apr 2026 18:30:00 -0400

Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, wishes to announce that the board of directors of the Company approved the grant of 200,000 incentive restricted stock units ("RSUs") to Mr. Sebastien Plouffe, CEO and Director of the Company, vesting immediately. Each RSU entitles the holder thereof to receive one common share of the Company expiring on April 24, 2027, subject to the terms of the Omnibus Incentive Plan of the Company and applicable securities law hold periods.

About Defence

Defence Therapeutics Announces Grant of Restricted Stock Units

Fri, 24 Apr 2026 18:30:00 -0400

Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, wishes to announce that the board of directors of the Company approved the grant of 200,000 incentive restricted stock units ("RSUs") to Mr. Sebastien Plouffe, CEO and Director of the Company, vesting immediately. Each RSU entitles the holder thereof to receive one common share of the Company expiring on April 24, 2027, subject to the terms of the Omnibus Incentive Plan of the Company and applicable securities law hold periods.
About Defence

Defence Therapeutics Announces Warrant Terms Amendment

Fri, 20 Mar 2026 18:00:00 -0400

Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce an amendment to the terms of a total of 800,000 Common Share purchase warrants (the "Warrants") originally issued as part of a private placement closed in 2024. The expiry date will be extended by 12 months and the exercise price will be repriced at $0.75 per Common Share, as follows:
No. of
Warrants: Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce an amendment to the terms of a total of 800,000 Common Share purchase warrants (the "Warrants") originally issued as part of a private placement closed in 2024. The expiry date will be extended by 12 months and the exercise price will be repriced at $0.75 per Common Share, as follows:
No. of
Warrants: Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private placement (the "Private Placement") of 17,445,455 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of $9,595,000.25. Each Unit is comprised of one common share (each, a "Share") and one common share purchase warrant ("Warrants"). Each Warrant entitles its holder to acquire an additional common share of the Company at a price of $0.65 per share

Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000

Mon, 09 Mar 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - March 9, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private placement (the "Private Placement") of 17,445,455 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of $9,595,000.25. Each Unit is comprised of one common share (each, a "Share") and one common share purchase warrant ("Warrants"). Each Warrant entitles its holder to acquire an additional common share of the Company at a price of $0.65 per share

Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March

Mon, 02 Mar 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum^® platform, today outlined its participation in a series of major international industry events taking place in March 2026.
These high-profile meetings will provide Defence with multiple opportunities to advance strategic partnerships, strengthen its global network, and further position Accum^® as a differentiated intracellular delivery technology for antibody-drug conjugates (ADCs), radiopharmaceutical conjugates (RDCs), and other complex biologics.
BIO-Europe Spring: Primary Focus on Strategic Partnerships
Defence will participate in BIO-Europe Spring

Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March

Mon, 02 Mar 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum^® platform, today outlined its participation in a series of major international industry events taking place in March 2026.
These high-profile meetings will provide Defence with multiple opportunities to advance strategic partnerships, strengthen its global network, and further position Accum^® as a differentiated intracellular delivery technology for antibody-drug conjugates (ADCs), radiopharmaceutical conjugates (RDCs), and other complex biologics.
BIO-Europe Spring: Primary Focus on Strategic Partnerships
Defence will participate in BIO-Europe Spring

Defence Therapeutics announces private placement for up to $11 million

Fri, 27 Feb 2026 17:02:10 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) announced a private placement offering of up to 20 million units at $0.55 per unit for gross proceeds of up to $11 million. Each unit consists of one common share and one warrant exercisable at $0.65 per share for 24 months.

The Montreal-based biotechnology company has executed a binding term sheet with two institutional investors for $6 million of the offering. Under a sharing agreement, the company will receive monthly cash payments of $333,333 over 18 months, beginning five months after closing.

The sharing agreement includes a benchmark price of $0.7332 per share.

Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million

Fri, 27 Feb 2026 17:00:00 -0400

Montreal, Quebec--(Newsfile Corp. - February 27, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the launch of a private placement (the "Private Placement") of up to 20,000,000 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of up to $11,000,000. Each Unit will be comprised of one common share (each, a "Share") and one common share purchase warrant ("Warrants"). Each Warrant will entitle its holder to acquire an additional common share of the Company at